Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim reports positive lung cancer trial data

Boehringer Ingelheim reports positive lung cancer trial data

10th December 2010

Boehringer Ingelheim has published new data which illustrates the potential benefits of its drug afatinib among certain lung cancer patient groups.

The therapy was trialled in the recent phase IIb/III LUX-Lung 1 clinical study, with results showing that the drug is effective among patients most likely to have an epidermal growth factor receptor (EGFR) mutation.

It was found that afatinib delivered a four-fold extension in progression-free survival rates in this group, while also showing a trend towards improved overall survival rates.

Previous afatinib data did not demonstrate this effect, but this is now thought to be due to the results being affected by the use of extensive subsequent therapies.

Dr Vincent Miller, principal investigator and medical oncologist at the Memorial Sloan-Kettering Cancer Center, said: "We continue to be encouraged by the findings of this study as we move towards personalised treatments."

Last month, the company released data showing the advantages offered by its compound BIBF1120 in the management of the lung condition idiopathic pulmonary fibrosis.ADNFCR-8000103-ID-800284080-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.